News

The company made this decision after completing phase 2 trials of the drug.

Developing technology may offer marked improvements in surgical precision

The price tag of publishing presents a tricky research barrier

Thomas V. Johnson, MD, PhD, notes the value of home monitoring lies in its ability to provide real-time insights into IOP fluctuations, enabling more precise glaucoma care and a deeper understanding of the patient's risk for vision loss.

The FDA has granted temporary discretion to import erythromycin ophthalmic ointment for the treatment of newborns.

In the data shared, switching to SB15 from AFL maintained comparable clinical efficacy and safety in treating patients with neovascular age-related macular degeneration (nAMD), confirming biosimilarity between these agents before and after switching.

This effort will advance screening technology at Canada’s foremost specialist care provider in diabetes and endocrinology.

Orasis Pharmaceuticals announces approval of Qlosi, a preservative-free, low-dose eye drop for presbyopia, which consistently demonstrated efficacy, safety, and tolerability in two pivotal Phase 3 trials.

Orasis Pharmaceuticals CEO Elad Kedar and COO Paul Smith sat down with David Hutton to discuss the FDA approval of Qlosi, a preservative-free low-dose eyedrops for presbyopia.

Eclipsing 100,000 doses sold to retinal specialists within the first full year after commercial launch is an important milestone for the company.

Phase 2/3 SIGLEC trial are underway. Data shared at EURETINA 2023 shows continued safety with no drug-related adverse events thus far in cohorts 1, 2, 3, and 4.

EVO ICLs, which evolved from early generation ICLs, offer a lens-based alternative for the correction/reduction of refractive error in people who currently use glasses and/or contact lenses for vision correction.

Mutations in the EMC1 gene appear to be associated with FEVR, a severe ocular condition.

According to a human study of older adults, grape intake improved macular pigment accumulation and downregulated harmful biomarkers.

Academy’s program will take place in San Francisco, California, 3-6 November 2023, before returning to Chicago, Illinois in 2024

Nathan Steinle, MD, spoke with Modern Retina's editor to give insights into his Retina Society presentation titled, "Phase 3 studies of dual inhibition of VEGF C/D and VEGF A using OPT-302 in combination With ranibizumab (ShORe Trial) or aflibercept (COAST Trial) in neovascular AMD."

Aldeyra Therapeutics encounters a significant setback, with its stock value plummeting nearly 70%. The FDA indicates a potential Complete Response Letter (CRL) for reproxalap, a dry eye treatment, despite a scheduled Prescription Drug User Fee Act (PDUFA) date of November 23, 2023.

At the 56th annual Retina Society congress in New York, David Boyer, MD, gave a presentation titled, "Subgroup analyses of phase 1 DAVIO Trial of EYP-1901 demonstrating reduced treatment burden in wet age-related macular degeneration."

In the wake of the October 7 surprise attack by Hamas, Israel finds itself thrust into war, and ophthalmologists are working to provide the best care they can under the conditions they find themselves in.

Sophie Bakri, MD, MBA, shared insights from her presentation, "Comparison of the Antiangiogenic Profile of Tyrosine Kinase Inhibitors Vorolanib, Axitinib, and Sunitinib."

Researchers note their work reports a novel candidate gene for FEVR, which expands the spectrum of EMC1 variants and EMC1-related phenotypes, providing evidence for the prenatal diagnosis of candidate disease-causing EMC1 variants in FEVR.

The patent covers the company’s development of this cell transplant therapy as a treatment for geographic atrophy.

According to the United States Attorney’s Office Southern District of Texas, Michael Hochman, MD, is set to be arraigned Oct. 12 before U.S. Magistrate Judge Christopher dos Santos.

With investigations into CVI in the early phases, collaboration across the Atlantic is crucial

AffaMed Technologies is the joint venture between AffaMed Therapeutics and SIFI.

The use of silicone-free syringes advised with these drops.

The Phase 3 DIAMOND trial of OCS-01 in Diabetic Macular Edema (DME) presents encouraging results, meeting primary and secondary endpoints.

Polish researchers found positive bacterial cultures in premature infants correlated with severe retinopathy of prematurity (ROP), suggesting a potential prognostic marker for early ROP development.